Experts say the government should carefully consider before signing free-trade agreements (FTA) - as people could be hurt by deals that prolong drug patents and restrict information about medicine.
New Zealand needs to be ready to walk away from the Trans Pacific Partnership, says The Domion Post, worried about the impact of its drug patenting rules and investor-state dispute settlement mechanism.
A recent draft of the Trans-Pacific Partnership free-trade deal would give US pharmaceutical firms unprecedented protections against competition from cheaper generic drugs, possibly transcending the patent protections in US law.
The Australian government misrepresents the claims of critics and fails to address substantial criticisms of the Trans Pacific Partnership, says civil society network AFTINET.
Recently leaked documents show that India’s policies on software and pharmaceutical patents are firmly on the RCEP agenda.
NZ is heading towards a two-tier health system, and it could get a whole lot worse, writes George Laking.
As the eighth round of negotiations on the Regional Comprehensive Economic Partnership (RCEP) trade agreement take place in Kyoto, Japan this week, farmer’s groups, trade unions, civil society and patient groups are urging the Indian Government to halt the negotiations, make the negotiating texts public and hold consultations with all the relevant stakeholders, in light of the potential negative impact this agreement could have on access to medicines, livelihood of farmers, quality public services and overall social and economic development of the country.
On Wednesday 10 June 2015, WikiLeaks published the Healthcare Annex to the secret draft "Transparency" Chapter of the Trans-Pacific Partnership Agreement (TPP), along with each country’s negotiating position.
Two-page summary of the main provisions in the Trans-Pacific Partnership Agreement (TPP) that will lead to higher prices for drugs and other medical technologies.
Trade negotiators for the Trans-Pacific Partnership agreement in Guam are now focusing on intellectual property issues, which appear likely to be the last hurdle to concluding the talks.
On Monday, a coalition of Peruvian civil society organizations issued a strong warning as negotiations for the Trans Pacific Partnership treaty (TPP) come to an end.
A new report from the prominent AIDS research group amfAR says that the Trans-Pacific Partnership would hamper the global fight against AIDS (and other diseases) in a way that would ultimately cost lives.
A text that Peru and 11 other countries (including the US) are negotiating in secret, seeks to expand drug patents for more than 20 years thus generating millions of overheads for our health system and making it even more difficult to obtain biological medicines against cancer.
Australia’s primary negotiator on medicines for the US-Australia FTA, Dr Ruth Lopert, warns that the TPP could force the Australian Government to spend hundreds of millions of dollars to subsidise medicines.
Chief negotiators in Trans-Pacific Partnership talks failed to iron out differences over the last week, with intellectual property protection on medicines and environmental protection being key stumbling blocks.
The US Ambassador Lippert has sent a letter to the Korean Minister of Food and Drug Safety requesting protection of biologics under the patent linkage system. He also confirmed that the US seeks the same protection in TPP.
TPP — the Trans-PacificPartnership — is making waves from Peru to Australia, concerning public health officials and consumer advocates.
Prof Brook K Baker, Professor of Law and Northeastern University, cautions that the Modi government’s accelerating flirtation with the US and its investors is dangerous to hundreds of millions of people worldwide whose lives depend on Indian generics
Access to affordable medicines could be under threat in Australia if the United States gets its way in secretive negotiations over a massive trade deal involving 12 Pacific-region countries, academics have warned.
Japan is pushing for intellectual property rules in the Regional Comprehensive Economic Partnership that will undermine and delay access to affordable generic medecine in Asia.